24 completed, 11 recruiting, 6 not yet recruiting, 5 unknown. 26 Not applicable, 7 Phase 2, 6 Phase 1, 4 Phase 3, 1 Early Phase 1.
Follow Weight Management: new trials by email Literature Review of Weight Management trials Research Report on Weight Management
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GLP-1 Impacts on Weight Management Weight Management, Disordered Eating Behaviors | Not yet recruiting | University of California, San Francisco | 100 | 2026-10-20 | 2026-10-13 | |
| TTM-Based Intervention for Weight Management Among High School Female Students Transtheoretical Model (TTM)-Based Behavioral Intervention for Weight Management - Weight Management | Not applicable | Not yet recruiting | University of Baghdad | 154 | 2026-10-10 | 2026-05-22 |
| Weight Management and Health Outcomes in College Students Weight Management - Weight Management, Health Outcomes | Not applicable | Not yet recruiting | Anhui Medical University | 200 | 2026-09-01 | 2026-09-24 |
| A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses HRS-1596, HRS-1596 Placebo - Weight Management, Type 2 Diabetes | Phase 1 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 122 | 2026-09-01 | 2026-09-25 |
| Weight Management After Cancer for Survivors in Rural Communities WeCan-Rural Program - Breast Cancer Survivorship, Weight Management | Not applicable | Recruiting | Duke University | 40 | 2026-08-31 | 2026-10-16 |
| A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control MN Nutra GeLiPthin-1™ Dietary Supplement, Placebo - Overweight, Obesity | Not applicable | Active not recruiting | MNnutra | 170 | 2026-08-27 | 2026-10-26 |
| A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants HRS9531 tablets - Weight Management, Type 2 Diabetes | Phase 1 | Not yet recruiting | Fujian Shengdi Pharmaceutical Co., Ltd. | 100 | 2026-07-01 | 2026-06-24 |
| A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM Elecoglipron, Placebo - Weight Management | Phase 3 | Recruiting | AstraZeneca | 4500 | 2026-06-29 | 2026-10-13 |
| A Controlled Study to Evaluate the Effects of a Supplement on Weight Loss, Blood Sugar, and Appetite Suppression Evolv GLP-1 Group, Control Group - Overweight, Obesity | Not applicable | Completed | Evolv | 98 | 2026-04-01 | 2026-10-22 |
| MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial ECC4703, Placebo, Semaglutide - Adult Obesity, Weight Management | Phase 2 | Active not recruiting | Eccogene | 151 | 2026-03-23 | 2026-06-25 |
| Usability Study of Gestational and Postpartum Weight Management Program Pregnancy, Postpartum | Recruiting | Turku University Hospital | 30 | 2025-12-09 | 2025-12-23 | |
| A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity ecnoglutide tablets, placebo with matching dosage - Overweight and/or Obesity, Weight Management | Phase 1 / Phase 2 | Recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 126 | 2025-11-18 | 2026-09-16 |
| CORE Study - Research Into Weight Management Services in the UK Weight Management | Enrolling by invitation | Society for Endocrinology | 41000 | 2025-09-12 | 2026-05-07 | |
| A Study of YP05002 in Healthy Participants YP05002, Placebo - Weight Management | Phase 1 | Completed | Yaopharma Co., Ltd. | 79 | 2025-08-19 | 2026-07-30 |
| A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH) XW003 injection, semaglutide injection - Obesity, Weight Management | Phase 2 | Active not recruiting | Hangzhou Sciwind Biosciences Co., Ltd. | 163 | 2025-07-28 | 2026-04-13 |
| Advancing Biopsychosocial Care Training Initiative Comprehensive Multidisciplinary Obesity Care, Implementation as Usual Control - Weight Management, Obesity Prevention | Not applicable | Recruiting | Washington University School of Medicine | 6200 | 2025-07-14 | 2026-08-10 |
| GV101 in Healthy Obese Participants GV101, GV101 placebo - Weight Management | Phase 2 | Completed | Graviton Bioscience Corporation | 131 | 2025-06-30 | 2026-02-04 |
| Ashwagandha Extract for Weight and Stress Management in Overweight and Obese Adults Ashwagandha 300 mg standardized root extract, Identical placebo capsule. - Weight Management, Stress | Not applicable | Completed | SF Research Institute, Inc. | 50 | 2025-06-17 | 2025-11-06 |
| Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity Ozempic® - Obesity and Overweight, Obese Adolescents | Recruiting | John Bauer | 50 | 2025-06-12 | 2026-07-21 | |
| Tolerance and Appetite Reduction of a Nutritional Solution With Intragastric Gelation Properties Beverage Variant 1 (low gelation properties), Beverage Variant 2 (medium gelation properties), Beverage Variant 3 (high gelation properties) - Weight Management | Not applicable | Completed | Société des Produits Nestlé (SPN) | 24 | 2025-05-22 | 2025-12-19 |
Showing 20 of 53. Sign in to see all of them.
Obesity (16) · Overweight (8) · Weight Loss (6) · Diabetes Mellitus, Type 2 (4) · Endometrial Neoplasms (3) · Motor Activity (2) · Neoplasms (2) · Agnosia (1) · Body Weight (1) · Breast Neoplasms (1) · Carcinoma, Medullary (1) · Cardiovascular Diseases (1) · Depression (1) · Diabetes Mellitus (1) · Disordered Eating Behavior (1)
Nutritional and Metabolic Diseases (21) · Pathological Conditions, Signs and Symptoms (21) · Signs and Symptoms (21) · Body Weight (18) · Nutrition Disorders (16) · Overnutrition (16) · Behavior (8) · Overweight (8) · Body Weight Changes (6) · Endocrine System Diseases (5) · Glucose Metabolism Disorders (5) · Metabolic Diseases (5) · Neoplasms (5) · Diabetes Mellitus (4) · Neoplasms by Site (4)
semaglutide (5) · Control Groups (2) · Exercise (2) · Amyloid Precursor Protein Secretases (1) · Ashwagandha (1) · Drug Therapy (1) · Glucagon-Like Peptide 1 (1) · Morus alba (1) · Naltrexone (1) · Omeprazole (1) · Shared Medical Appointments (1) · Transtheoretical Model (1) · Vitamins (1) · bupropion hydrochloride, naltrexone hydrochoride drug combination (1)
Fujian Shengdi Pharmaceutical Co., Ltd. (3) · Hangzhou Sciwind Biosciences Co., Ltd. (3) · Duke University (2) · Peking University People's Hospital (2) · Acibadem University (1) · AgelessRx (1) · Anhui Medical University (1) · Ascletis Pharma (China) Co., Limited (1) · AstraZeneca (1) · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo (1) · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (1) · Case Western Reserve University (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Concordia University Wisconsin (1) · DuPont Nutrition and Health (1)
United States (25) · China (10) · Canada (4) · Spain (3) · United Kingdom (3) · Australia (2) · Hong Kong (2) · India (2) · Italy (2) · Turkey (Türkiye) (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · Chile (1) · Finland (1)
Linong Ji, Dr (2) · Alexandra Jenkins, PhD (1) · Annette Stemhagen, DrPH, FISPE (1) · Aurelia Radulescu, MD (1) · Caroline Dorfman, PhD (1) · Caroline S Dorfman, PhD (1) · Charlene W Compher, PhD (1) · Christopher Gardner, PhD (1) · Denise Wilfley, Ph.D. (1) · Dr. Ania Jastreboff, MD, PhD (1) · Eva Almiron-Roig, PhD (1) · Jennifer Logue, MBChB PhD (1) · Jintong Li, Dr (1)
PMID 21194471, PMID 22554310, PMID 30767902, PMID 33179845, PMID 40555243, PMID 41605251, PMID 41799945, PMID 42801445
2025 (1), R01CA105292 (1), R01DK134961 (1)